NeilJShahMD

Hematologic Oncology

Physician

Overview of Dr. Shah

Dr. Neil Shah is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Pramukhswami Medical College and has been in practice 7 years. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 30 publications and over 500 citings.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(256) 693-2804

Education & Training

MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2016 - 2019
Hackensack University Medical Center (Mountainside)Residency, Internal Medicine, 2012 - 2016
Pramukhswami Medical CollegeClass of 2010

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2014 - 2025
NY State Medical License 2019 - 2024
DC State Medical License 2016 - 2020
VA State Medical License 2017 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

28 citations
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Andrew Schmidt, Matthew D Tucker, Ziad Bakouny, Chris Labaki, Chih-Yuan Hsu
JAMA Network Open. 2021-11-01
87 citations
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J. Shah, Ghassan Al-Shbool, Matthew Blackburn, Michael R. Cook, Anas Belouali
Journal for Immunotherapy of Cancer. 2019-12-17
10 citations
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Kelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha
European Urology. 2023-03-01

Lectures

Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, a...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

New Combo Immunotherapy Prolongs Survival in Patients with Advanced Kidney CancerApril 22nd, 2022
Patient Groups Untested in Cancer Immunotherapy Trials Found to Also BenefitMay 30th, 2019